



#1  
Patent Application  
Attorney Docket No. PC10901A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: BANKS, ET AL. :

APPLICATION NO.: 09/779,413 : Examiner: Not Yet Assigned

FILING DATE: FEBRUARY 8, 2001 : Group Art Unit: Not Yet Assigned

TITLE: USE OF PYRIMIDINE ENDOTHELIN :  
ANTAGONISTS IN COMPANION  
ANIMALS

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: May 18, 2001

Lorraine B. Ling  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251

Pfizer Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-2030

INFORMATION DISCLOSURE STATEMENT, 3/99, (I/1)

05/24/2001 RECEIVED 00000067 161445 09779413

01 FC:126

183.00 CH

Express Mail No. EL639818392US